Visit Provider
  • Top 25 lowest monthly cost · Flat-rate pricing
  • No commitment required · Cancel anytime
  • Prescription included · Online questionnaire, no video call · Dose adjustment supported · Free consultation
  • Additive-free options · Multiple pharmacy options · Third-party tested
  • Free expedited shipping · Discreet packaging
  • Tirzepatide, Semaglutide
  • Available in all 50 states with some pharmacy restrictions
  • Auto-renewing plans

Provider Plans

1-Month Plan
TirzepatideMonthly
$145/avg
PharmacyHallandale (503A)
Vials Rx (503A)Greenwich (503A)Align (503A)Boudreaux's New Drug Store (503A)Rush (503A)
AdditivesNone or B3
PreservativeBenzyl Alcohol
BUD (Shelf Life)90 or 180 Days
BillingMonthly
CommitmentNo Commitment
Other FeesNo Extra Fees
Auto-RenewsYes
DoseYour SupplyYour PriceYour SupplyAvg/moYour Value
1.5mg/wk6mg/mo$145.006mg$145$24.17/mg
3.0mg/wk12mg/mo$145.0012mg$145$12.08/mg
6.0mg/wk24mg/mo$145.0024mg$145$6.04/mg
9.0mg/wk36mg/mo$145.0036mg$145$4.03/mg
11.0mg/wk44mg/mo$145.0044mg$145$3.30/mg
13.5mg/wk54mg/mo$145.0054mg$145$2.69/mg
The product page offers a 1-month and a 3-month term behind a selector, and only the 1-month price renders. The 3-month price is not in the page text or its markup, so no 3-month plan is staged rather than one being inferred.
Non-standard FDA doses

Provider Details

Fully Online Care

In-House RxDose Adjustments By Provider
Prescription IncludedYes
Telehealth IncludedYes
Online-Only OptionYes
Skip LabsNot Disclosed

Self-Pay

Credit
Insurance AcceptedNo
HSA/FSA AcceptedNot Disclosed
Financing AvailableNot Disclosed

LegitScript Certified

40,000+ Patients
LegitScript CertifiedYes
HIPAA CompliantYes
Mobile AppNot Disclosed

Free Express Shipping

Cold-Packed
Free ShippingYes
Expedited ShippingYes
Discreet PackagingYes

Tirz + Sema · 503A

Format: Injection
Offers TirzepatideYes
Offers SemaglutideYes
Offers BrandNo
Other TreatmentsYes

Provider Notes

Compliance

The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.